Division of Geriatric Medicine, Saint Louis University School of Medicine and GRECC, VA Medical Center, St. Louis, MO 63104, USA.
J Am Med Dir Assoc. 2011 Jul;12(6):403-9. doi: 10.1016/j.jamda.2011.04.014.
A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. "Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.
肌少症、恶病质和消耗性疾病学会召开了一次共识会议，会议得出结论：“肌少症，即肌肉量减少伴活动能力受限”应被视为一种重要的临床实体，大多数老年人都应接受这种情况的筛查。“伴活动能力受限的肌少症”定义为肌肉丧失的人，其步行速度等于或小于 1 m/s，或在 6 分钟步行测试中行走少于 400 m，且瘦体质量校正身高平方的平均值低于同种族 20 至 30 岁健康人的 2 个标准差。活动能力受限不应明显是其他定义明确的肌肉疾病、间歇性跛行的外周血管疾病、中枢和外周神经系统疾病或恶病质的结果。有临床意义的干预措施定义为 6 分钟步行至少增加 50 米或步行速度至少增加 0.1 m/s。
